Immuno-Oncology | Specialty

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

September 14th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14th 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Dr. Kim on Combination Therapies in Lung Cancer

September 13th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

September 12th 2016

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

Nivolumab Maintains Positive Results in Latest HCC Findings

September 11th 2016

Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

September 8th 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC

September 8th 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

FDA Grants Pembrolizumab Priority Review in Frontline NSCLC

September 7th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a first-line treatment for patients with PD-L1–positive non–small cell lung cancer.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Prognostic Tool for Immuno Age Debuts

September 6th 2016

An assay that would evaluate the immune status of patients with colon cancer is poised to become the first of a series of Immunoscore tests for various tumor types.

Expert Discusses Next Steps With Immunotherapy in Melanoma

September 2nd 2016

Yvonee Saenger, MD, discusses ongoing developments with immunotherapy in melanoma.

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Atezolizumab Improves Survival in Phase III Lung Cancer Study

September 1st 2016

Atezolizumab (Tecentriq) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Leora Horn on Toxicities With Immunotherapy in Lung Cancer

August 31st 2016

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

August 30th 2016